Heart Diseases (Heart Disease)

02/01/2006 - " For the best protection against clogged arteries and heart disease, average cholesterol no longer makes the grade--lower is better."
12/01/1995 - "A systematic examination of the evidence on the relationship between serum cholesterol and ischaemic heart disease shows conclusively that serum cholesterol reduction in populations with high rates of heart disease is an effective and safe method of reducing ischaemic heart disease rates. "
01/01/2014 - "To examine whether a cholesterol-lowering diet is more effective in reducing ischaemic heart disease and lowering cholesterol than no dietary intervention in children and adults with familial hypercholesterolaemia. "
01/01/2010 - "To examine whether a cholesterol-lowering diet is more effective in reducing ischaemic heart disease and lowering cholesterol than no dietary intervention in children and adults with familial hypercholesterolaemia. "
12/01/2005 - "It is now accepted that inhibition of cholesterol biosynthesis is effective in the primary and secondary prevention of heart disease. "

03/01/1985 - "We conclude that there are some Echo-Phonocardiographic signs which are very useful in the diagnosis and measurement of pulmonary arterial hypertension in children with congenital heart disease."
09/20/2013 - "Efficacy of exercise training in pulmonary arterial hypertension associated with congenital heart disease."
12/01/2014 - "24 patients with congenital heart disease-associated pulmonary arterial hypertension, including 4 receiving heart surgery and 20 with surgical contraindications, were enrolled in this study. "
11/01/2013 - "The present study aims to determine the relationship between the cardiac catheterization findings and PW Doppler and Doppler tissue imaging (DTI) in patients who have pulmonary arterial hypertension patients due to congenital heart disease with intracardiac shunts. "
11/01/2013 - "The aim of this study is to determine the relationship between the cardiac catheterization findings and pulsed-wave (PW) Doppler and Doppler tissue imaging (DTI) in pulmonary arterial hypertension patients with congenital heart disease with intracardiac shunts. "

11/01/1996 - "The combination of the two drug tests, electrophysiologic study and Holter monitoring, is a useful method for the prediction of the long-term efficacy of amiodarone in patients with sustained VT and underlying heart disease. "
01/01/2005 - "Amiodarone was more effective for preventing recurrence in patients with poorer left ventricular function and underlying heart disease."
03/01/2014 - "Amiodarone (AMI) is a low water-solubility drug, which is very useful in the treatment of severe cardiac disease. "
11/01/1986 - "Thus, in patients with frequent VPCs and no underlying heart disease, oral intake of T3 during amiodarone treatment is safe and does not abolish the antiarrhythmic efficacy of amiodarone, despite a shortening of the QTc.(ABSTRACT TRUNCATED AT 250 WORDS)"
07/13/1999 - "Amiodarone is widely used in adults with congenital heart disease, but no systematic study has been published on its effects on thyroid function in these patients. "

04/01/1990 - "Further studies are required to establish the clinical importance of cardioprotection by ACE-inhibitors in ischaemic heart disease."
04/01/1990 - "However, these cardioprotective effects have not yet been shown in patients with ischaemic heart disease, although some studies indicate that ACE-inhibitors are also able to cause anti-ischaemic effects in patients. "
05/14/2012 - "The ERI was higher in patients with a history of heart disease or HF and those treated with drugs acting on the renin-angiotensin system (ACE inhibitors or ARBs). "
04/01/2010 - "Detecting latent myocardial involvement is essential in this disease because early use of drugs like angiotensin-converting enzyme inhibitors may delay the progression of heart disease. "
12/01/2008 - "Some of these changes can be summarized as follows: Basis therapy includes betablockers and - in patients with structural heart disease - ACE-inhibitors and AT(1)-Blockers respectively. "

09/09/2003 - "Intravenous sildenafil is as effective as inhaled NO as a pulmonary vasodilator in children with congenital heart disease. "
05/01/2010 - "We sought to determine the efficacy of postoperative oral sildenafil therapy (OST) in pediatric patients with congenital heart disease (CHD). "
07/01/2014 - "For children with high altitude heart disease associated with severe PAH, sildenafil can effectively reduce pulmonary artery pressure and improve cardiac function and does not cause adverse reactions. "
01/01/2014 - "Acute onset of bilateral visual loss during sildenafil therapy in a young infant with congenital heart disease."
12/01/2013 - "Sildenafil improves clinical and functional status of an elderly postmenopausal female with 'out of proportion' PH associated with left heart disease."

03/17/2009 - "What aspirin dose is safest and most effective for preventing heart disease?"
10/01/2001 - "Already used by millions of patients with heart diseases, aspirin could be a useful protection against contractile dysfunction of the obstructed bladder."
01/01/2015 - "Overall there were no observed significant differences in risk of cardiac disease at one year between corticosteroid-treated and aspirin-treated groups (six studies, 907 participants, risk ratio 0.87, 95% confidence interval 0.66 to 1.15). "
01/01/2012 - "Overall there was no significant difference in the risk of cardiac disease at one year between the corticosteroid-treated and aspirin-treated groups (six studies, 907 participants, relative risk 0.87, 95% confidence interval 0.66 to 1.15). "
08/01/2009 - "This study characterised the prevalence of aspirin resistance in patients with ischaemic heart disease (IHD) and investigated the concordance and repeatability of these tests. "

11/15/2011 - "The aim of this study was to retrospectively analyze the long-term efficacy and safety of bosentan in adults with PAH secondary to congenital heart disease (PAH-CHD). "
11/01/2006 - "However, there are limited studies examining the benefits of bosentan in PAH associated with congenital heart disease (CHD). "
07/01/2012 - "Bosentan is the only medication to date to be compared with placebo in a randomized controlled trial specifically targeting congenital heart disease-associated PAH. "
05/01/2007 - "To evaluate safety, tolerability, and clinical and haemodynamic effects of bosentan in patients with PAH related to congenital heart disease (CHD). "
09/01/2006 - "Pre-clinical data support the rationale for the potential benefit of bosentan in PAH associated with congenital heart disease (CHD). "

11/01/2010 - "Palivizumab has proven efficacy for prophylaxis of respiratory syncytial virus (RSV) in infants with prematurity or congenital heart disease. "
12/01/2008 - "In spite of these factors, RSV prophylaxis using palivizumab in premature children with BPD or hemodynamically significant congenital-heart disease can be considered cost-effective in France."
10/01/2003 - "To evaluate the safety, tolerance, and efficacy of palivizumab in children with hemodynamically significant congenital heart disease (CHD). "
12/01/2000 - "(6) Given the lack of relevant trials, we do not know if palivizumab is effective in infants with immunodeficiency or congenital heart diseases. "
10/01/2015 - "This study was designed to investigate the efficacy of palivizumab prophylaxis among infants with congenital heart disease (CHD) in Turkey. "

01/01/1991 - "Although there is good evidence in many forms of heart disease that complex VEBs indicate a high risk of death, treatment of asymptomatic VEBs with antiarrhythmic drugs has not been shown to improve survival and may be hazardous. "
10/01/2000 - "EAT in children without underlying heart disease can be effectively treated using antiarrhythmic drugs. "
01/01/2012 - "There is little data on the long-term efficacy of antiarrhythmic drugs (AADs) and radiofrequency catheter ablation (RFCA) in patients with symptomatic premature ventricular complexes (PVCs) and no organic heart disease. "
02/01/1993 - "The clinical outcome is critically dependent on the type and degree of underlying heart disease, symptoms at presentation, inducibility at electrophysiology study, and responses to antiarrhythmic drugs. "
01/01/1990 - "This study was performed to evaluate the effects of antiarrhythmic drugs on left ventricular function in 843 patients with ischaemic heart disease and ventricular arrhythmias (Lown classes 2-5). "

11/25/1991 - "These benefits have not been established by a randomized trial, however, so that the degree of protection against heart disease might have been overestimated because estrogen users tend to be healthier than nonusers. "
07/09/1999 - "These novel observations may help to explain the role of estrogen in gender-based differences found in cardiac disease."
07/01/1997 - "To assess the efficacy of unopposed estrogen, and three estrogen/progestin regimens on selected heart disease risk factors among adherent women and to contrast those results with efficacy among all women in the PEPI study. "
01/01/2006 - "While these findings have led to a revision of guidelines such that they discourage the use of estrogen for primary or secondary prevention of heart disease in postmenopausal women, many investigators have attributed the negative results in clinical trials to several flaws in study design, including the older age of study participants and the initiation of estrogen late after menopause.Because"
01/21/2003 - "Risk factors and secondary prevention in women with heart disease: the Heart and Estrogen/progestin Replacement Study."

11/01/2007 - "Despite being accepted as the best treatment for end-stage heart diseases, the long-term benefit of heart transplantation in children remains a matter of controversial debate. "
03/01/2000 - "Cardiac transplantation provides the best option for neonates with congenital heart disease that is not amenable to surgical repair or palliation. "
02/01/1999 - "With a survival rate of 70% at 3 years, cardiac transplantation is the best treatment for end-stage heart disease. "
10/01/1993 - "Our data demonstrate that after heart transplantation prognosis of end-stage cardiac disease is highly improved either for life expectancy and for quality of life. "
01/01/1989 - "Cardiac transplantation now is a proven, effective surgical procedure for people with end stage heart disease. "

01/01/2009 - "Surgical outcomes for patients with congenital heart disease have improved dramatically over the past few decades due, in part, to improvements in preoperative and postoperative management, cardiopulmonary bypass and intraoperative technique, and the development of pediatric cardiology as a subspecialty. "
12/01/1995 - "Although these data suggest that the leukocyte filter offers little clinical benefit, a prospective, randomized study should be undertaken to further elucidate the efficacy of leukocyte depletion for infants undergoing cardiopulmonary bypass for correction of congenital heart disease."
01/01/2016 - "The study comprised 29 children with congenital heart disease, who underwent corrective surgery including cardiopulmonary bypass. "
03/01/2015 - "One hundred and twenty-eight consecutively transfused children undergoing repair or palliation of congenital heart disease with cardiopulmonary bypass who were participating in a randomized trial of washed versus standard RBC transfusions were evaluated for an association of RBC storage age and clinical outcomes. "
03/01/2015 - "Patients operated for acquired heart diseases with cardiopulmonary bypass (CPB) were included in the study (n = 51, age: 58 ± 11 years). "

10/01/2010 - "Endovascular stent implantation is a highly effective and safe means of relieving noncoronary vascular obstruction in patients with congenital and acquired structural heart disease. "
01/01/2005 - "Stent implantation is a technically feasible, safe and effective palliative option in high-risk surgical patients with congenital heart disease and reduced pulmonary blood flow. "
09/01/2004 - "Transcatheter stent implantation for treatment of a significant residual PPAS after surgical correction of complicated congenital heart disease is a safe and effective procedure. "
08/01/2014 - "This study investigates a CP stent (Numed, USA) used in congenital heart disease applications with a focus on the variance in measurements of stent geometry. "
01/01/2010 - "RESOLUTE was a prospective, multicentre, non-randomised, single-arm, controlled trial of the Resolute stent in 139 participants with symptomatic ischaemic heart disease due to single de novo lesions in a native coronary artery. "

09/01/1997 - "We conclude that low energy "unipolar" internal cardioversion is a simple, safe, and effective technique for termination of chronic AF in patients with heart disease. "
08/01/1994 - "In patients who were in sinus rhythm both those with and without underlying heart disease improved, and improvement was not related to functional capacity or left ventricular function before cardioversion. "
05/11/2005 - "The study group, comprised of 81 patients with persistent AF, with underlying hypertensive heart disease, consecutively referred for elective direct current cardioversion. "
05/01/2003 - "The aim of the study was to evaluate the time course of atrial and ventricular function improvement following internal atrial cardioversion in patients with structural heart disease. "
12/01/2014 - "While transesophageal cardioversion is very successful in humans and research animals, this technique has not been previously described in a clinical patient with naturally occurring heart disease in veterinary medicine. "

12/01/2004 - "As a result of recent technological advances, more types of congenital heart disease are amenable to treatment in the cardiac catheter laboratory than ever before.1 Improved imaging techniques allow for better selection of patients, and the development of a wide range of devices specifically for use in children means that many patients can avoid surgery altogether, while those with complex congenital heart disease may require fewer or less complex surgical procedures.2 This allows for a quicker recovery and a shorter hospital stay, and gives many patients an improved quality of life in the short to medium term. "
06/01/1998 - "These data indicate that catheter intervention in young adults with congenital heart diseases is as effective as in children."
01/01/2011 - "In general, echocardiography and cardiac catheter angiography are considered the gold standard for the evaluation of congenital heart disease. "
06/01/1998 - "The efficacy of catheter intervention for adult congenital heart diseases was evaluated in 27 patients aged 20 to 52 years (mean age at catheterization 25 +/- 7 years) from 1986 to 1996. "
10/01/2014 - "We sought to describe radiation exposure and the effectiveness of radiation safety protocols in reducing exposure during catheter ablations with electrophysiology studies in children and patients with congenital heart disease. "